Guj. Themis Bio.
Drug Manufacturers - Specialty & Generic · GUJTHEM
Small CapHealthcareHigh Growth
Tapas Guha Thakurata
Chief Executive Officer · Pragmatic
Company DNA
Innovation-Led
About
Guj. Themis Bio. is a Small Cap company in the Healthcare sector, listed on NSE as GUJTHEM. With a market cap of ₹3K Cr and revenue of ₹151 Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Operating in specialty pharma with a focus on high-growth niche therapeutic areas necessitates an R&D-centric, experimentation-oriented work environment. Its strategic mandate: Requires heavy R&D focus and intellectual property development to scale its niche pharmaceutical offerings and compete globally.
FAQ
What kind of company is Guj. Themis Bio.?
Guj. Themis Bio. is a Small Cap Healthcare company (GUJTHEM) in the High Growth phase with a market cap of ₹3K Cr. It is classified as Innovation-Led in culture.
What is Guj. Themis Bio.'s culture and work environment like?
Guj. Themis Bio. has a Innovation-Led culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Operating in specialty pharma with a focus on high-growth niche therapeutic areas necessitates an R&D-centric, experimentation-oriented work environment.
Who leads Guj. Themis Bio.?
Guj. Themis Bio. is led by Tapas Guha Thakurata (Chief Executive Officer), a Pragmatic leader with 30 years of experience.
What are Guj. Themis Bio.'s financials?
Guj. Themis Bio. reported revenue of ₹151 Cr in FY25 with a 5-year revenue CAGR of 9.7%. Operating margin: 42.1%. Market cap: ₹3K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleHigh Growth
Operating in specialty pharma with a focus on high-growth niche therapeutic areas necessitates an R&D-centric, experimentation-oriented work environment.
Mandate
Requires heavy R&D focus and intellectual property development to scale its niche pharmaceutical offerings and compete globally.
Requires heavy R&D focus and intellectual property development to scale its niche pharmaceutical offerings and compete globally.
Financials
Revenue FY25₹151 Cr
PAT FY25₹49 Cr
Rev CAGR 5Y9.7%
OPM42.1%
NPM32.3%
ROE19.6%
ROCE22.6%
P/E64.1
Fwd P/E—
P/B11.6
D/E27
Mkt Cap₹3K Cr
Promoter72%
Institutional1.2%
Similar Culture
Could You Lead Guj. Themis Bio.?
Take the Genome Benchmark →